Researchers at Stanford have developed a novel cell-free stem cell derived extracellular vesicle (EV) therapy powered by pulsed focused ultrasound (pFUS) that enhances its therapeutic and bioenergetic effect.
Researchers in Prof. Mark Kay's laboratory have developed variant AAV (adeno-associated virus) vectors with specificity and high transduction efficiency for pancreatic alpha- and beta- islet cells.
Stanford researchers have invented a method and developed compositions of matter to reduce the production of infectious viruses in cells that line the respiratory tract. The invention enables the use of gene-silencing approaches to prevent and treat viral infections.
A major barrier in CAR-T cell therapies has been T cell exhaustion, which affects the durability and effectiveness of treatments, particularly for solid tumors.
The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
Researchers at Stanford have developed a methodology for deep learning-based image reconstruction by incorporating the physics or geometry priors of the imaging system with deep neural networks.
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.
Stanford researchers have developed a new controllable methodology for molecularly targeted ultrasound contrast agent production with pre-formed ligand-phospholipid bioconjugates.
Researchers at Stanford have developed synthetic transcription elongation factors (Syn-TEFs) to treat proliferative diseases, including repeat expansion mutations in cancer.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.
Researchers in Prof. Matthew Scott's laboratory have discovered that small-molecule inhibitors of casein kinase II (CK2) could be used as a targeted therapy for pediatric medulloblastoma or other Shh/hedgehog-related tumors.
Stanford researchers at the Zhao Lab have developed a wireless, magnetically actuated amphibious origami millirobot that can locomote in narrow spaces and morph their shapes. The researchers have demonstrated that this millirobot can travel on surfaces and through liquid.